Search

You searched for "VEGF"

210 results found

New mouse model of diabetes mellitus

1 April 2014 | | EYE - Vitreo-Retinal
Diabetic retinopathy (DR) is a serious complication of diabetes. It is driven by the loss of pericytes, cells which control vascular function, due to excess formation of sugar alcohols by the enzyme aldose reductase (AR). AR has been shown to...
Seminars in Ophthalmology journal cover image

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

5 October 2020 | | EYE - Vitreo-Retinal
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...
Ophthalmologica journal cover image

Update: Non-infectious retinal vasculitis

2 December 2024 | | EYE - Vitreo-Retinal
This review article summarises the update on non-infectious retinal vasculitis (RV). It is primarily classified based on the type of retinal vessels involved and further sub-classified as occlusive or nonocclusive. Clinically it can occur as an isolated ocular entity or...

Data update for leading causes of CVI in England and Wales

1 August 2016 | | EYE - General, EYE - Strabismus, EYE - Paediatrics
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...

Strategies for managing neovascular AMD and DMO in routine clinical care

1 October 2015 | | EYE - Vitreo-Retinal
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

My top five: Uses of artificial intelligence in ophthalmology

3 August 2023 | | EYE - General
Artificial Intelligence (AI) has emerged as a prominent topic of discussion within the field of ophthalmology, captivating researchers and practitioners alike. Although recent attention has been drawn to the integration of AI in ophthalmology, it’s important to recognise that AI...

My Top Five: Uses of artificial intelligence in ophthalmology

3 August 2023 | | EYE - General
Artificial Intelligence (AI) has emerged as a prominent topic of discussion within the field of ophthalmology, captivating researchers and practitioners alike. Although recent attention has been drawn to the integration of AI in ophthalmology, it’s important to recognise that AI...

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | EYE - General
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

The role of injection assistant devices in establishing a nurse-led AMD service

1 April 2018 | | EYE - Vitreo-Retinal
The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Safety and efficacy of a nurse-led intravitreal injection service using an Precivia® injection assist device

1 December 2021 | | EYE - Vitreo-Retinal, EYE - General
Nurse-led intravitreal injections have become of great importance for busy eye units. In this article, the authors present safety data from five years of a nurse-led service with the use of the Precivia® intravitreal injection assist device. Intravitreal injections of...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

3 April 2023 | | EYE - General
Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

Management of proliferative diabetic retinopathy

1 August 2014 | | EYE - Vitreo-Retinal
Diabetic retinopathy is a major cause of blindness in the working-age population. Due to the worsening global epidemic of diabetes, the incidence of morbidity caused by the disease is set to increase [1]. The prevalence of diabetes in the UK...